Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: An individual participant data meta-analysis of randomized controlled trials

Diabetes, Obesity and Metabolism

Volumn 17, Issue 5, 2015, Pages 505-510

  Seshasai, S R K ^a   Bennett, R L ^a   Petrie, J R ^b   Bengus, M ^c   Ekman, S ^c   Dixon, M ^d   Herz, M ^c   Buse, J B ^e   Ray, K K ^f  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular safety; Diabetes; GLP 1 receptor agonists; Meta analysis; Taspoglutide

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN GLARGINE; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; TASPOGLUTIDE; PEPTIDE;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSTABLE ANGINA PECTORIS; AGONISTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; MALE; MIDDLE AGED; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84926138389     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12448     Document Type: Article

References (21)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
3. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D etal. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
4. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009; 94: 1843-1852.
5. Chia CW, Egan JM. Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes 2009; 2: 37.
6. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010; 123(Suppl. 3): S28-37.
7. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P etal. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439.
8. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med 2013; 369: 1285-1287.
9. Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J, Boldrin M etal. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care 2012; 35: 485-487.
10. Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R etal. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care 2013; 36: 498-504.
11. Henry RR, Mudaliar S, Kanitra L, Woloschak M, Balena R. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab 2012; 97: 2370-2379.
12. Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther 2012; 3: 13.
13. Nauck M, Horton E, Andjelkovic M, Ampudia-Blasco FJ, Parusel CT, Boldrin M etal. Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with type 2 diabetes: an open-label randomized trial. Diabet Med 2013; 30: 109-113.
14. Pratley RE, Urosevic D, Boldrin M, Balena R. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). Diabetes Obes Metab 2013; 15: 234-240.
15. Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Sunyer FX etal. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring) 2013; 21: 238-247.
16. A study of taspoglutide in patients with inadequately controlled diabetes mellitus type 2 and cardiovascular disease. https://clinicaltrials.gov/ct2/show/NCT01018173, 2009
17. A study to compare taspoglutide and insulin glargine in insulin-naïve patients with type 2 diabetes mellitus inadequately controlled on metformin and sulfonylurea combination therapy. https://clinicaltrials.gov/ct2/show/NCT01051011?term=ZC22565&rank=1, 2010
18. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 22.
19. Marso SP, Lindsey JB, Stolker JM et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011; 8: 237-240.
20. Monami M, Cremasco F, Lamanna C et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011; 2011: 215764.
21. Meloni AR, DeYoung MB, Han J, Best JH, Grimm M. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol 2013; 12: 48.